Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial

As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 21...

Descripción completa

Detalles Bibliográficos
Autores principales: Matino, Erica, Tavella, Elena, Rizzi, Manuela, Avanzi, Gian Carlo, Azzolina, Danila, Battaglia, Antonio, Becco, Paolo, Bellan, Mattia, Bertinieri, Giovanni, Bertoletti, Massimo, Casciaro, Giuseppe Francesco, Castello, Luigi Mario, Colageo, Umberto, Colangelo, Donato, Comolli, Davide, Costanzo, Martina, Croce, Alessandro, D’Onghia, Davide, Della Corte, Francesco, De Mitri, Luigi, Dodaro, Valentina, Givone, Filippo, Gravina, Alessia, Grillenzoni, Luca, Gusmaroli, Graziano, Landi, Raffaella, Lingua, Anna, Manzoni, Roberto, Marinoni, Vito, Masturzo, Bianca, Minisini, Rosalba, Morello, Marina, Nelva, Anna, Ortone, Elena, Paolella, Rita, Patti, Giuseppe, Pedrinelli, Anita, Pirisi, Mario, Ravizzi, Lidia, Rizzi, Eleonora, Sola, Daniele, Sola, Mariolina, Tonello, Nadir, Tonello, Stelvio, Topazzo, Gigliola, Tua, Aldo, Valenti, Piera, Vaschetto, Rosanna, Vassia, Veronica, Zecca, Erika, Zublena, Nicoletta, Manzoni, Paolo, Sainaghi, Pier Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10005739/
https://www.ncbi.nlm.nih.gov/pubmed/36904283
http://dx.doi.org/10.3390/nu15051285
Descripción
Sumario:As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63–1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) ≤ 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70–1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19.

Ejemplares similares